2022
DOI: 10.21203/rs.3.rs-2030964/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Insights and Current Perspectives on Pharmacogenomics of Antimalarial Drugs

Abstract: Malaria constitutes a major public health concern in tropical and other malaria-endemic regions. Genetic and non-genetic factors are known to influence the pharmacokinetics and/or pharmacodynamics of drugs including antimalarial drugs resulting in variability in drug responses. This article aimed to update perspectives on pharmacogenomics and also provide an updated appraisal of genetic variability in drug-metabolizing enzymes which alter the disposition of antimalarial drugs causing variations in treatment ou… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 52 publications
0
1
0
Order By: Relevance
“…Lastly, CYP3A4 and CYP3A5 enzymes with poor-metabolizer phenotypes (CYP3A4*22, CYP3A5*3, CYP3A5*6, and CYP3A5*7) have been linked with quinine adverse reactions [ 207 , 208 , 209 ]. The impact of CYP genetic variants on antimalarial drugs and their clinical implications has also been reviewed in a recent article by Soyinka et al 2022 [ 210 ].…”
Section: Polymorphism In Cyp Enzymes With Specific Focus On Antimalar...mentioning
confidence: 99%
“…Lastly, CYP3A4 and CYP3A5 enzymes with poor-metabolizer phenotypes (CYP3A4*22, CYP3A5*3, CYP3A5*6, and CYP3A5*7) have been linked with quinine adverse reactions [ 207 , 208 , 209 ]. The impact of CYP genetic variants on antimalarial drugs and their clinical implications has also been reviewed in a recent article by Soyinka et al 2022 [ 210 ].…”
Section: Polymorphism In Cyp Enzymes With Specific Focus On Antimalar...mentioning
confidence: 99%